28WWW.CEN-ONLINE.ORG MAY 18, 2009

INVITROGEN and Applied Biosystems (AB) tied the knot last November and be-came Life Technologies, a power couple in laboratory supply. Despite the stormy economy, the new company’s honeymoon period has been relatively sunny.

Invitrogen, a life sciences reagents provider, bought AB, an instrument and

reagents company with particular strength in ge-netics, molecular biology, and mass spectrometry, in a cash and stock transac-tion valued at $6.7 billion. The deal created a firm that offers a wide range of consumables and instruments for the life sciences market.

The new company generates more than 70% of its sales from consumables, ranging from immunoassay reagents to cell-culture media. That reliance on consumables may stand the company in good stead during these tumultuous times. Even with the tough economic climate, Life Technolo-gies’ revenues grew by 1% in the first quar-ter of this year compared with the same pe-riod in 2008 (calculated as if the two com-panies had been one for the whole year).

The financial results show “how essen-tial our products are to the everyday work of our customers,” said Gregory T. Lucier,

chairman and chief executive officer, speaking in a conference call with industry analysts late last month. “Our products are just about the last thing to be cut because of the criticality of them in our customers’ ever-important work.”

Life Technologies is organized into four technology-based divisions. Its revenues

for 2008, again calculated as if the two firms had been one, were $3.14 billion. The original company names will survive as platform brands.

Mark Smedley, the executive head-ing up the integration effort, says the combined company can offer scien-tific researchers more than 50,000 products. “Now you have an organiza-tion that has an unmatched breadth of reagents and instruments that you can use those reagents on,” he says.

The benefits from the merger flow both ways, Smedley argues. “On the AB side, they have access to a portfolio of 30,000 reagents they didn’t have. We can do a lot of work on extending those matched reagent-instrument pairs,” he points out. Invitrogen, in turn, will benefit from AB’s expertise in genetics and molecular biology.

The two companies used slightly different business models, Smedley says. Invitrogen’s model was “very

transactional,” with average order sizes around $500. AB, in contrast, was selling high-priced instruments such as mass spectrometers, which are often considered capital equipment.

These differences meant that the respective sales forces targeted differ-ent parts of each customer’s hierarchy. “Invitrogen was really around the bench scientist, and AB had really good rela-tionships with management and funding decisionmakers,” Smedley says. “Put the two companies together, and now you have complete account coverage.”

The combined Life Technologies cur-rently has five sales forces, focusing on

mass spectrometry, sequencing, reagents, other instruments, and service. “Over time, we will reduce the number of sales forces, but not necessarily the number of salespeople, so that we’re more stream-lined in front of the customer into essen-tially what will be a reagents sales force and an instruments sales force,” Smedley says.

MUCH OF the company’s integration effort has focused on combining the two research programs into a single portfolio. R&D managers have selected the best projects and jettisoned ones that don’t fit the com-pany’s vision of its joint future.

Now that Life Technologies has made those initial decisions, it is starting to ex-plore new areas, such as personalized and regenerative medicine. In the short term, that means focusing on DNA sequencing. The company expects to spend more than $100 million on sequencing-related R&D this year, Smedley says. “That’s an area that we think is going to transform how

BUSINESS

BECOMING LIFE TECHNOLOGIES

NEWLYWEDS Invitrogen and Applied Biosystems get to know one another

CELIA HENRY ARNAUD , C&EN WASHINGTON

LIF

E T

EC

HN

OL

OG

IES

TWO BECOME ONE The Invitrogen and Applied Biosystems names live on at Life Technologies.

Life Technologies At A Glance

Headquarters: Carlsbad, Calif.Revenues: $3.14 billionNumber of employees: 9,500R&D spending: $323 million

BUSINESSES(% of sales):Molecular biology systems (47%):

Polymerase chain reaction systems, molecular biology reagents, genomic assays

Genetic systems (27%): Capillary electrophoresis, next-generation DNA sequencing

Cell systems (25%): Cell analysis, cell culture, primary stem cell systems

Other (1%): Mass spectrometry revenues not part of the joint venture

Website: www.lifetechnologies.com

NOTE: Revenue and R&D figures are pro forma results from Life Technologies, calculated as if In-vitrogen and Applied Biosystems had been a single company for all of 2008. Life Technologies is also involved in Mass Spectrometry Systems, a joint venture with MDS Analytical Technologies that had $525 million in sales last year.

Dow Biocides and Rohm and Haas are now working together

as Dow Microbial Control to provide you with the first and only

complete portfolio of microbial control technologies and expertise.

Get access to the highest-performing portfolio of environmentally

preferred products backed by the world leader in application

expertise and customer support—all under one roof. For every

market, for every challenge, we can help you formulate a solution.

There are more of us to ask. So please, feel free to ask more of us.

See how Dow Microbial Control can take you beyond biocides.

Please visit us at www.dowmicrobialcontrol.com

for the latest updates and a free gift.

30WWW.CEN-ONLINE.ORG MAY 18, 2009

science is done and in which we believe we have what we need to be a world leader.”

Life Technologies has brought its re-search team together for workshops to talk about trends in science and industry and to evaluate where each of the legacy compa-nies was in its respective research program. The goal is to determine which areas have the most scientific and business potential. “The great thing,” Smedley says, “is that we have far more ideas than we can fund.”

THE COMBINATION of the two firms won’t endanger what was AB’s long-standing mass spectrometry joint venture with partner MDS Analytical Technologies, Smedley insists. “That’s a good business,” he says. “It’s one that we’re going to contin-ue to run for success.” In fact, the joint ven-ture announced a major product launch, a new time-of-flight mass spectrometer, just last month.

The combination of Invitrogen and AB echoes the 2006 merger of Thermo Elec-tron and Fisher Scientific into Thermo Fisher Scientific in that it joined a firm focused on instruments with one focused

on lab consumables. Yet observers point to important differences.

“Invitrogen and AB took the area that Thermo Fisher is probably the least exposed to,” says Quintin Lai, an industry analyst at Robert W. Baird, referring to the genetics and molecular biology markets. “They can coexist without butting heads against each other too often. That’s what made this com-bination like the Thermo Fisher deal and yet not directly in competition with Thermo Fisher. It’s very rare that you get these kinds of megamergers and there’s not a whole lot of overlap between the two big giants.”

The results Life Technologies reported last month were for its first full quarter as a combined company. The 1% growth in total revenue brought $785 million to the combined company. The firm’s operating margin increased 1.9% to 26.2%, primarily as a result of synergy realization.

“Our business remains good despite the economy,” Lucier said in the confer-ence call. “Our industry in general and our company in particular tends to be relatively resilient in tough economic times.”

Life Technologies says it is well on its

way to capturing $80 million in planned cost synergies during 2009. It claims to have achieved $50 million of it already, largely in the areas of corporate overhead, distribution, and procurement.

The company also expects to generate substantial revenue synergies, although time will tell whether it succeeds. It plans to use Invitrogen’s aggressive price optimiza-tion strategy on AB’s product lines.

“Because Invitrogen had a very trans-actional business and a large portfolio with a large number of customers, we’ve developed a sophisticated group that is focused on how you price effectively,” Smedley says. “We find that our customers are relatively price insensitive.” Hence, the company has successfully raised prices each year.

The company also plans to focus on in-creasing the number of customers who use Invitrogen or AB reagents with AB instru-ments. “Razors and razor blades—that’s a business model we like,” Smedley says. “If your mission is scientific output, whether it’s commercial research or general re-search, you have to use a reagent.” ■

Pora Pak™ Rxn products are designed to ensure fast and thorough cleanup of most

synthesis reactions. T he polymer used in PoraPak Rxn material is tolerant of pH

extremes, shows low hydraulic resistance and displays very little shrinking or

swelling in organic solvents. T his combination of physical and chemical properties

makes PoraPak Rxn an ideal solution for your most challenging synthesis cleanup.

X NR> I F Q V Z

C^pq�@ib^krm�lc�Pvkqebpfp�Ob^`qflkp

©2009 Waters Corporation. Porapak and The Science of What’s Possible are trademarks of Waters Corporation.

Post Synthesis Cleanup

PoraPakTM

ttt+t^qbop+`lj,mlo^m^h1